Examining the Clinical Effectiveness of Non-Carbapenem beta-Lactams for the Treatment of Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae

被引：2

作者：

Gibble, Allison M. ^{[1
,2
]}

Gross, Alan E. ^{[3
]}

Huang, Angela M. ^{[1
,2
]}

机构：

[1] Froedtert, Dept Pharm, Milwaukee, WI 53226 USA

[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[3] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA

来源：

ANTIBIOTICS-BASEL | 2015年 / 4卷 / 04期

关键词：

extended-spectrum beta-lactamases; piperacillin-tazobactam; cefepime; carbapenems;

D O I：

10.3390/antibiotics4040653

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Treatment options for extended-spectrum -lactamase-producing Enterobacteriaceae are limited. Piperacillin-tazobactam and cefepime represent potential alternative treatment options; however, large prospective studies are lacking. This review evaluates the current literature regarding use of piperacillin-tazobactam and cefepime for the treatment of extended-spectrum -lactamase-producing Enterobacteriaceae. Antimicrobial stewardship programs can play a key role in guiding the best practices for the management of these challenging infections.

引用

页码：653 / 666

页数：14